Literature DB >> 21739531

Urinary tract infections in hospitalized inflammatory bowel disease patients: a 10-year experience.

Laurent Peyrin-Biroulet1, Claire Pillot, Abderrahim Oussalah, Vincent Billioud, Nejla Aissa, Mamadou Balde, Nicolas Williet, Adeline Germain, Alain Lozniewski, Laurent Bresler, Jean-Louis Guéant, Marc-André Bigard.   

Abstract

BACKGROUND: Cystitis is the most common genitourinary complication in Crohn's disease (CD). We assessed the prevalence of and risk factors for urinary tract infections (UTI) in inflammatory bowel diseases (IBD).
METHODS: Among the 1173 IBD patients of the "Nancy IBD cohort" seen between January 1, 2000 and December 31, 2009, 56 hospitalized patients had 76 documented UTI. Prevalence of UTI in IBD was calculated using rates of UTI among non-IBD patients hospitalized during the same period. The cases were compared to 175 matched IBD patients without UTI hospitalized during the same period to identify risk factors for UTI.
RESULTS: Prevalence of UTI was 4% in IBD patients versus 3.3% in non-IBD patients (P = 0.1). Prevalence of UTI was 4.5% and 2.1% in ulcerative colitis (UC) and CD patients, respectively (P = 0.6). Risk factors for UTI in CD patients were perianal disease (odds ratio [OR] = 2.28, 95% confidence interval [CI], 1.06-4.89; P = 0.04) and colonic disease (OR = 2.42, 95% CI, 1.05-5.58; P = 0.04). Male gender (OR = 0.38, 95% CI, 0.17-0.85, P = 0.02) and noncomplicated behavior (OR = 0.26, 95% CI, 0.11-0.60, P = 0.002) were protective factors against UTI in CD. In UC patients, age over 40 years (OR = 9.59, 95% CI, 1.93-47.74; P = 0.006) and disease duration over 11 months (OR = 10.77, 95% CI, 1.68-68.89, P = 0.01) were risk factors for UTI. Male gender was negatively associated with UTI (OR = 0.04, 95% CI, 0.01-0.36, P = 0.00006).
CONCLUSIONS: Hospitalized IBD patients are not at increased risk of UTI. Risk factors for UTI include perianal disease and colonic disease in CD and age and longer disease duration in UC.
Copyright © 2011 Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21739531     DOI: 10.1002/ibd.21777

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  5 in total

1.  Genetic risk factors for serious infections in inflammatory bowel diseases.

Authors:  Saranya Sasidharan; Vijay Yajnik; Hamed Khalili; John Garber; Ramnik Xavier; Ashwin N Ananthakrishnan
Journal:  Scand J Gastroenterol       Date:  2017-02-05       Impact factor: 2.423

2.  Urinary manifestations in African American and Caucasian inflammatory bowel disease patients: a retrospective cohort study.

Authors:  Jake Herbert; Emily Teeter; Landen Shane Burstiner; Ralfi Doka; Amor Royer; Anna H Owings; Julia Liu; Sarah C Glover; Pegah Hosseini-Carroll
Journal:  BMC Urol       Date:  2022-01-04       Impact factor: 2.264

3.  Adverse Clinical Outcomes among Inflammatory Bowel Disease Patients Treated for Urinary Tract Infection.

Authors:  Offir Ukashi; Yiftach Barash; Eyal Klang; Tal Zilberman; Bella Ungar; Uri Kopylov; Shomron Ben-Horin; Ido Veisman
Journal:  J Clin Med       Date:  2022-03-01       Impact factor: 4.241

4.  Phylogrouping and characterization of Escherichia coli isolated from colonic biopsies and fecal samples of patients with flare of inflammatory bowel disease in Iran.

Authors:  Banafsheh Nadalian; Bahareh Nadalian; Hamidreza Houri; Shabnam Shahrokh; Mohammad Abdehagh; Abbas Yadegar; Gholamhossein Ebrahimipour
Journal:  Front Med (Lausanne)       Date:  2022-08-29

5.  Metabolomic profiles are gender, disease and time specific in the interleukin-10 gene-deficient mouse model of inflammatory bowel disease.

Authors:  Victor K Tso; Beate C Sydora; Rae R Foshaug; Thomas A Churchill; Jason Doyle; Carolyn M Slupsky; Richard N Fedorak
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.